Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer

American Journal of Obstetrics and Gynecology

Volumn 203, Issue 2, 2010, Pages 160.e1-160.e7

  Havrilesky, Laura J ^a   Krivak, Thomas C ^b   Mucenski, John W ^c   Myers, Evan R ^a  

^a DUKE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

chemoresponse assay; cost analysis; ovarian cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; PACLITAXEL; TOPOTECAN;

ARTICLE; CANCER CHEMOTHERAPY; COST CONTROL; DRUG COST; DRUG MARKETING; DRUG SCREENING; EMPIRICAL RESEARCH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RECCURRENT OVARIAN CANCER; RECURRENT CANCER; RECURRENT OVARIAN CANCER; REIMBURSEMENT; TREATMENT RESPONSE;

EID: 77955661839     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.02.054     Document Type: Article

References (16)

1. R.F. Ozols, B.N. Bundy, B.E. Greer, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
2. A. du Bois, H.J. Luck, W. Meier, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320 1329
3. J.P. Neijt, S.A. Engelholm, M.K. Tuxen, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer J Clin Oncol 18 2000 3084 3092
4. P.A. Vasey, G.C. Jayson, A. Gordon, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma J Natl Cancer Inst 96 2004 1682 1691
5. W.P. McGuire III, and M. Markman Primary ovarian cancer chemotherapy: current standards of care Br J Cancer 89 Suppl 2003 S3 S8
6. M. Markman Pharmaceutical management of ovarian cancer: current status Drugs 68 2008 771 789
7. P. Kornblith, A. Wells, M.J. Gabrin, et al. In vitro responses of ovarian cancers to platinums and taxanes Anticancer Res 23 2003 543 548
8. P. Kornblith, A. Wells, M.J. Gabrin, et al. Breast cancer-response rates to chemotherapeutic agents studied in vitro Anticancer Res 23 2003 3405 3411
9. P. Kornblith, R.L. Ochs, A. Wells, et al. Differential in vitro effects of chemotherapeutic agents on primary cultures of human ovarian carcinoma Int J Gynecol Cancer 14 2004 607 615
10. R.L. Ochs, J. Fensterer, N.P. Ohori, et al. Evidence for the isolation, growth, and characterization of malignant cells in primary cultures of human tumors In Vitro Cell Dev Biol Anim 39 2003 63 70
11. D.H. Kern, C.R. Drogemuller, M.C. Kennedy, et al. Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors Cancer Res 45 1985 5436 5441
12. D.H. Kern, and L.M. Weisenthal Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures J Natl Cancer Inst 82 1990 582 588
13. V.K. Sondak, C.A. Bertelsen, N. Tanigawa, et al. Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay Cancer Res 44 1984 1725 1728
14. J.P. Fruehauf In vitro assay-assisted treatment selection for women with breast or ovarian cancer Endocr Relat Cancer 9 2002 171 182
15. H. Gallion, W.A. Christopherson, R.L. Coleman, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay Int J Gynecol Cancer 16 2006 194 201
16. J.W. Orr Jr, P. Orr, and D.H. Kern Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance Cancer J Sci Am 5 1999 174 178